Evkeeza (evinacumab-dgnb) is a fully-human monoclonal antibody that works by blocking the action of a protein called angiopoietin-like 3 (ANGPTL3). When Evkeeza blocks the action of ANGPTL3, "bad" cholesterol (known as LDL cholesterol) can be cleared from the body in patients with Homozygous Familial Hypercholesterolemia (HoFH).